The Effect Of Microneedle Therapy On Chronic Pain And Post-Operative Analgesia

https://en.wikipedia.org/wiki/Microneedles

Chronic pain affects over 1.5 billion people worldwide and is a leading cause of disability. However, existing treatments are suboptimal: oral analgesics often cause gastrointestinal, hepatic, and renal toxicity; local corticosteroid injections are effective but repeated punctures exacerbate tissue damage; and opioids face a crisis of addiction. Microneedle therapy offers a new paradigm for pain management-achieving "effective analgesia without side effects" through precise drug delivery and physical modulation.

In neuropathic pain treatment, microneedles demonstrate unique advantages. Conditions like postherpetic neuralgia and diabetic peripheral neuropathy traditionally require oral Gabapentin or Pregabalin, which cause central side effects like drowsiness and dizziness at high doses. Microneedle patches can deliver Lidocaine or Capsaicin at a controlled rate locally, acting directly on peripheral nerve endings and avoiding systemic exposure. Clinical studies show that a single 60-minute application of an 8% Capsaicin microneedle patch reduced pain scores by an average of 50% in postherpetic neuralgia patients, with analgesic effects lasting up to 12 weeks. In contrast, oral Gabapentin, while analgesic, requires three daily doses and half of the patients report significant side effects.

Microneedles are also remarkably effective in managing osteoarthritis pain. Knee osteoarthritis is the most common source of pain in middle-aged and elderly individuals. Traditional treatments include oral NSAIDs and intra-articular Hyaluronic Acid injections. Oral drugs are limited by gastrointestinal irritation, while injections require professional administration and carry infection risks. Microneedle patches can deliver Ketoprofen or Diclofenac Sodium transdermally at a constant rate to the soft tissues surrounding the joint, achieving local anti-inflammatory and analgesic effects. A double-blind trial involving 200 knee osteoarthritis patients showed that after two weeks of treatment with a Ketoprofen microneedle patch, the WOMAC index improved by 58%, equivalent to oral Celecoxib, but with only one-third the incidence of gastric discomfort.

In the field of post-operative analgesia, the value of microneedles is equally significant. Traditional post-surgical pain management relies on IV patient-controlled analgesia (PCA) pumps or oral opioids; the former requires indwelling catheters (increasing infection risk), while the latter often causes nausea and constipation. Microneedle Ropivacaine patches can provide 12 to 24 hours of local anesthesia around the incision, significantly reducing opioid requirements. Comparative studies in orthopedic surgery showed that patients using microneedle analgesic patches consumed 40% less morphine within 24 hours post-op, began ambulating 6 hours earlier, and had their hospital stay shortened by 1.5 days.

The analgesic effect of microneedling is not solely dependent on drugs; the physical stimulation itself also has analgesic properties. According to the Gate Control Theory, the tactile pressure signals generated by microneedling can competitively inhibit the transmission of pain signals, similar to Transcutaneous Electrical Nerve Stimulation (TENS). This dual "pharmacological + physical" mechanism gives microneedling a unique status in pain management-it does not simply suppress pain, but restores the body's balance at multiple levels.